Hannah Janee Compton, PA-C

Hannah Compton practices at Texas Oncology PA in Dallas, Texas.

Hannah Compton's NPI, 1437516002, was assigned on January 27, 2016.

Hannah Compton's primary practice is Texas Oncology PA, at 3410 Worth St, Dallas, TX 75246 in Dallas County. The practice phone is (972) 997-8000.

Hannah Compton's primary practice is Texas Oncology PA in Dallas, Texas. The medical group on file is HealthTexas Provider Network (HTPN). Dmand AI also links Hannah Compton to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Hannah Compton practices, 2 sites in all. Vendor and product names are available with a free account.

Physician assistant is Hannah Compton's primary specialty in the NPI Registry, under taxonomy code 363A00000X.

Dmand AI lists tobacco use among the conditions Hannah Compton treats.

CMS data shows 1,010 Medicare services from Hannah Compton across 8 procedure codes in 2024, for 198 Medicare patients. Medicare paid $53,756 for them. Every service was in an office.

CMS counts 198 Medicare patients who saw Hannah Compton in 2024. The largest group is 65 to 74, with 109 patients. 74% of them have high cholesterol, and 73% have high blood pressure. 6% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Hannah Compton's median patient age at 68, with 36% women.

In 2024, Hannah Compton wrote 388 Medicare Part D claims for 117 patients. 86% of them were for generic drugs. CMS names the drug for 234 of them, across 12 drugs with 11 or more claims each, at $10,200 in total drug cost.

Hannah Compton accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Hannah Compton as offering telehealth.

CMS Open Payments shows 32 general payments to Hannah Compton from 10 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $222.